Novel phenylpiperazine derivatives as dual cytokine regulators with TNF-α suppressing and IL-10 augmenting activity

Bioorganic and Medicinal Chemistry Letters

Volumn 10, Issue 9, 2000, Pages 875-879

  Hanano, Tokushi ^a   Adachi, Kunitomo ^b   Aoki, Yoshiyuki ^b   Morimoto, Hiroshi ^b   Naka, Yoichi ^b   Hisadome, Masao ^b   Fukuda, Tetsuko ^b   Sumichika, Hiroshi ^b  

^a Drug Discovery Laboratories   (Japan)

^b Drug Development Laboratories   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 10; PIPERAZINE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG ACTIVITY; DRUG BINDING; DRUG SYNTHESIS; FEMALE; MOUSE; SEPTIC SHOCK; STRUCTURE ANALYSIS;

ANIMALS; BIOLOGICAL AVAILABILITY; CENTRAL NERVOUS SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; INTERLEUKIN-10; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED BALB C; PIPERAZINES; RATS; RECEPTORS, CYTOKINE; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA;

EID: 0034192606     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(00)00128-1     Document Type: Article

References (40)

1. (a) Macnaul, K. L.; Hutchinson, N. I.; Parsons, J. N.; Bayne, E. K.; Tocci, M. J. J. Immunol. 1990, 145, 4154.
2. (b) Brennan, F. M. ; Gibbons, D. L.; Mitchell, T.; Cope, A. P.; Maini, R. N.; Feldmann, M. Eur. J. Immunol. 1992, 22, 1907.
3. Dullemen H.M.V., Deventer S.J.H.V., Hommes D.W., Bijl H.A., Jansen J., Tytgat G.N.J., Woody J. Gastroenterology. 109:1995;129.
4. Maury C.P.J., Teppo A.-M. Arthritis Rheum. 32:1989;146.
5. (a) Sharief, M. K.; Hentges, R. N. Engl. J. Med. 1991, 325, 467.
6. (b) Beck, J.; Rondot, P.; Catinot, L.; Falcoff, E.; Kirchner, H.; Wietzerbin, J. Acta. Neurol. Scand. 1988, 78, 318. (c) Hofmann, F. M.; Hinton, D. R.; Merrill, J. E. J. Exp. Med. 1989, 170, 607.
7. (b) Beck, J.; Rondot, P.; Catinot, L.; Falcoff, E.; Kirchner, H.; Wietzerbin, J. Acta. Neurol. Scand. 1988, 78, 318. (c) Hofmann, F. M.; Hinton, D. R.; Merrill, J. E. J. Exp. Med. 1989, 170, 607.
8. (d) Gallo, P.; Piccinno, M. G.; Krzalic, L.; Tavolato, B. J. Neuroimmunol. 1989, 23, 41.
9. Lechner A.J., Tredway T.L., Brink D.S., Klein C.A., Matuschak G.M. Am. J. Physiol. 263:1992;L526.
10. Makonkawkeyoon S., Limson-Pombre R.N.R., Moreira A.L., Schauf V., Kaplan G. Proc. Natl. Acad. Sci. USA. 90:1993;5974.
11. (a) Elliott, M. J.; Maini, R. N.; Feldmann, M.; Long-Fox, A.; Charles, P.; Katsikis, P.; Brennan, F. M.; Walker, J.; Bijl, H.; Ghrayeb, J.; Woody, J. N. Arthritis Rheum. 1993, 36, 1681.
12. (b) Dullemen, H. M. V.; Deventer, S. J. H. V.; Hommes, D. W.; Bijl, H. A.; Jansen, J.; Tytgat, G. N. J.; Woody, J. Gastroenterology 1995, 109, 129.
13. (a) Niwayama, S.; Turk, B. E.; Liu, J. O. J. Med. Chem. 1996, 39, 3044.
14. (b) Muller, G. W.; Corral, L. G.; Shire, M. G.; Wang, H.; Moreira, A.; Kaplan, G.; Stirling, D. I. J. Med. Chem. 1996, 39, 3238.
15. (c) Miyachi, H.; Azuma, A.; Ogasawara, A.; Uchimura, E.; Watanabe, N.; Kobayashi, Y.; Kato, F.; Kato, M.; Hashimoto, Y. J. Med. Chem. 1997, 40, 2858.
16. Yamamoto N., Sakai F., Yamazaki H., Kawai Y., Nakahara K., Okuhara M. J. Rheumatol. 23:1996;1778.
17. Borcherding D.R., Peet N.P., Munson H.R., Zhang H., Hoffman P.F., Bowlin T.L., Edwards C.K. III J. Med. Chem. 39:1996;2615.
18. Kleinman E.F., Campbell E., Giordano L.A., Cohan V.L., Jenkinson H.J., Cheng J.B., Shirley J.T., Pettipher E.R., Salter E.D., Hibbs T.A., DiCapua F.M., Bordner J. J. Med. Chem. 41:1998;266.
19. Mosmann T.M. Advances in Immunology. 56:1994;1.
20. (a) Kucharzik, T.; Stoll, R.; Lugering, N.; Domschke, W. Clin. Exp. Immunol. 1995, 100, 452.
21. (b) Maini, R. N.; Paulus, H.; Breedveld, F. C.; Moreland, L. W.; Clair, E. W. St.; Russell, A. S.; Charles, P.; Davies, D.; Grint, P.; Wherry, J. C.; Feldmann, M. Arthritis Rheum. 1997, 40, S224.
22. (a) Isomaki, P.; Luukkainen, R.; Saario, R.; Toivanen, P.; Punnonen, J. Arthritis Rheum. 1996, 39, 386.
23. (b) Chernoff, A. E.; Granowitz, E. V.; Shapiro, L.; Vannier, E.; Lonnemann, G.; Angel, J. B.; Kennedy, J. S.; Rabson, A. R.; Wolff, S. M.; Dinarello, C. A. J. Immunol. 1995, 154, 5492.
24. 2: Creese, L.; Schneider, R.; Snyder, S. H. Eur. J. Pharmacol. 1977, 46, 377.
25. 1A: Hall, M. D.; Mestikawy, S. E.; Emerit, M. B.; Pichat, L.; Hamon, M.; Gozlan, H. J. Neurochem. 1985, 44, 1685.
26. 2: Leysen, J. E.; Niemegeers, J. E.; Neeten, J. M. V.; Laduron, P. M. Molecular Pharmacol. 1981, 21, 301.
27. 1: Greengrass, P.; Bremner, R. Eur. J. Pharmacol. 1979, 55, 323.
28. Compounds 5a-k and 7a-c gave satisfactory analytical and spectroscopic data in accord with their assigned structures.
29. Estrada A., Van Kessel A., Yun C.H., Li B. Immunopharmacology and Immunotoxicology. 20:1998;217.
30. In control mice, TNF-α plasma concentration reached maximum 90 min after LPS injection while IL-10 plasma concentration reached maximum within the range of 90-120 min after LPS injection. Our preliminary examination using anti IL-10 antibody showed that both TNF-α and IL-10 may be independently regulated since pretreatment of mice with anti IL-10 antibody did not affect the degree of TNF-α suppression by active compounds in LPS-injected mice
31. Compound 2 was readily prepared from 1-phenylpiperazine and (4-bromobutyl)benzene synthesized starting from commercially available (4-hydroxybutyl)benzene.
32. (a) Strader, C. D.; Sigal, I. S.; Candelore, M. R.; Rands, E.; Hill, W. S.; Dixon, R. A. F. J. Biol. Chem. 1988, 263, 10267.
33. (b) Mansour, A.; Meng. F.; Meador-Woodruff, J. H.; Taylor, L. P.; Civelli, O.; Akil, H. Eur. J. Pharmacol. 1992, 227, 205.
34. (c) Chanda, P. K.; Minchin, M. C. W.; Davis, A. R.; Greenberg, L.; Reilly, Y.; McGregor, W. H.; Bhat, R.; Lubeck, M. D.; Mizutani, S.; Hung, P. P. Mol. Pharmacol. 1993, 43, 516.
35. (d) Ho, B. Y.; Karschin, A.; Branchek, T.; Davidson, N.; Lester, H. A. FEBS Lett. 1992, 312, 259.
36. (f) Wang, C.; Gallaher, T. K.; Shih, J. C. Mol. Pharmacol, 1993, 43, 931.
37. 3O: C, 66.84; H, 6.45; N, 11.69%. Found: C, 66.84; H, 6.43; N, 11.66%.
38. The effect of 5k on shock was studied as follows. Compound 5k was orally administered (10 mg/kg) to female BALB/c mice (n=10/group) 30 min prior to intraperitoneal injection of LPS (Escherichia coli 055:B5) at a dose of 15 mg/kg. Survival was monitored 72 h after LPS injection.
39. 0-24h, and BA of 5k were 9.26 μg/ml, 3.80 h, 123.22 μgh/mL, and 95.5%, respectively.
40. -6 M in vitro.